Clinical outcome of reflex EGFR mutation and ALK fusion testing in patients with non-squamous non-small cell lung cancer

National Registry of Diseases Office SCR, Interim Annual Registry Report: Trends in Cancer Incidence in Singapore 2009-2013, 2014 Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N. Engl. J. Med., 361, 947, 10.1056/NEJMoa0810699 Maemondo, 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N. Engl. J. Med., 362, 2380, 10.1056/NEJMoa0909530 Wu, 2015, First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study, Ann. Oncol., 10.1093/annonc/mdv270 Soda, 2007, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 448, 561, 10.1038/nature05945 Shaw, 2013, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N. Engl. J. Med., 368, 2385, 10.1056/NEJMoa1214886 Solomon, 2014, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N. Engl. J. Med., 371, 2167, 10.1056/NEJMoa1408440 Lindeman, 2013, J. Mol. Diagn., 15, 415, 10.1016/j.jmoldx.2013.03.001 Leighl, 2014, J. Clin. Oncol., 32, 3673, 10.1200/JCO.2014.57.3055 Bae, 2007, EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients, Cancer Genet. Cytogenet., 173, 107, 10.1016/j.cancergencyto.2006.10.007 Schmid, 2009, EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases, Clin. Cancer Res., 15, 4554, 10.1158/1078-0432.CCR-09-0089 Shi, 2014, A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER), J. Thorac. Oncol., 9, 154, 10.1097/JTO.0000000000000033 Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N. Engl. J. Med., 350, 2129, 10.1056/NEJMoa040938 Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 1497, 10.1126/science.1099314 Pao, 2004, EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib, Proc. Natl. Acad. Sci. USA, 101, 13306, 10.1073/pnas.0405220101 Sakairi, 2010, EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration, Clin. Cancer Res., 16, 4938, 10.1158/1078-0432.CCR-10-0099 Wong, 2009, The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS, Cancer, 115, 1723, 10.1002/cncr.24181 Rodig, 2009, Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population, Clin. Cancer Res., 15, 5216, 10.1158/1078-0432.CCR-09-0802 Shaw, 2009, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK, J. Clin. Oncol., 27, 4247, 10.1200/JCO.2009.22.6993 Paik, 2012, Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma, Lung Cancer, 76, 403, 10.1016/j.lungcan.2011.11.008 Tufman, 2014, Preselection based on clinical characteristics in German non-small-cell lung cancer patients screened for EML4-ALK translocation, J. Thorac. Oncol., 9, 109, 10.1097/JTO.0000000000000043 The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM), A genomics-based classification of human lung tumors. Sci. Transl. Med., 2013, 5:209ra153 Moreira, 2014, Personalized therapy for lung cancer, Chest, 146, 1649, 10.1378/chest.14-0713